Section Arrow
INSM.NASDAQ
- Insmed
Quotes are at least 15-min delayed:2024/12/23 22:12 EST
Last
 70.59
+0.15 (+0.21%)
Day High 
70.903 
Prev. Close
70.44 
1-M High
78.83 
Volume 
1.10M 
Bid
70.52
Ask
73.2
Day Low
68.8 
Open
70.25 
1-M Low
68.6724 
Market Cap 
12.60B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 72.04 
20-SMA 73.26 
50-SMA 72.34 
52-W High 80.53 
52-W Low 21.92 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.55/-3.70
Enterprise Value
13.80B
Balance Sheet
Book Value Per Share
2.70
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
305.21M
Operating Revenue Per Share
1.57
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed:2024/12/23 22:12 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.